Abstract
Mycophenolate Mofetil (MMF) is an important immunosuppressant prodrug prescribed to prevent organ transplant rejection and to treat autoimmune diseases. MMF usage, however, is limited by severe gastrointestinal toxicity that is observed in approximately 45% of MMF recipients. The active form of the drug, mycophenolic acid (MPA), undergoes extensive enterohepatic recirculation by bacterial β-glucuronidase (GUS) enzymes, which reactivate MPA from mycophenolate glucuronide (MPAG) within the gastrointestinal tract. GUS enzymes demonstrate distinct substrate preferences based on their structural features, and gut microbial GUS enzymes that reactivate MPA have not been identified. Here, we compare the fecal microbiomes of transplant recipients receiving MMF to healthy individuals using shotgun metagenomic sequencing. We find that neither microbial composition nor the presence of specific structural classes of GUS genes are sufficient to explain the differences in MPA reactivation measured between fecal samples from the two cohorts. We next employed a GUS-specific activity-based chemical probe and targeted metaproteomics to identify and quantify the GUS proteins present in the human fecal samples. The identification of specific GUS enzymes was improved by using the metagenomics data collected from the fecal samples. We found that the presence of GUS enzymes that bind the flavin mononucleotide (FMN) is significantly correlated with efficient MPA reactivation. Furthermore, structural analysis identified motifs unique to these FMN-binding GUS enzymes that provide molecular support for their ability to process this drug glucuronide. These results indicate that FMN-binding GUS enzymes may be responsible for reactivation of MPA and could be a driving force behind MPA-induced GI toxicity.
Competing Interest Statement
J.R.L. receives research support from BioFire Diagnostics, LLC. J.R.L. is an inventor on patent US-2020-0048713-A1, entitled: METHODS OF DETECTING CELL-FREE DNA IN BIOLOGICAL SAMPLES. M.R.R. is a founder of Symberix, Inc., which is developing microbiome-targeted therapeutics. M.R.R. also receives research funding from Merck and Eli Lilly.
Funding Statement
This work was supported by NIH grants GM137286 (M.R.R.) and K32 AI 124464 (J.R.L.) by the Eshelman Institute for Innovation at UNC Chapel Hill (M.R.R.) and by NSF DGE-1650116 (J.B.S) and a Career Development Award from the Crohns and Colitis Foundation (APB). Metagenomic sequencing provided by the UNC Microbiome Core Facility was funded by CGIBD P30 DK034987 and NORC P30 DK056350. Metaproteomic sequencing provided by the Proteomics Core Facility is supported in part by P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
From May 2019 to January 2020, five male kidney transplant recipients were enrolled for collection of fecal specimens. The Weill Cornell Institutional Review Board approved the study (IRB#1207012730) and all transplant recipients provided written informed consent. Fecal samples were also collected from four healthy male volunteers at the University of North Carolina at Chapel Hill as approved by IRB Approval Board at Human Subjects Research Office of Human Research Ethics at The University of North Carolina at Chapel Hill under IRB#17-1528.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author information updated
Data Availability
Metagenomic and metaproteomic sequencing data derived from the kidney transplant patients will be made available at accession number phs001879 in the database of Genotypes and Phenotypes (dbGaP) upon publication.57 Approval from a local institutional review board approval will be needed to obtain the data. Sequencing data derived from healthy individuals will be made available at the Integrated Data Management and Comparative Analysis System for Microbial Genomes and Microbiomes Database (IMG/MER) upon publication. The metaproteomics data and protein sequence database for healthy individuals [will be] deposited to the ProteomeXchange Consortium via the PRIDE repository.
